The N-terminal 303 amino acids of the human cytomegalovirus envelope glycoprotein B (UL55) and the exon 4 region of the major immediate early protein 1 (UL123) induce a cytotoxic T-cell response

Vaccine

Volumn 14, Issue 5, 1996, Pages 369-374

  Berencsi, Klara ^a   Gönczöl, Eva ^a   Endresz, Valeria ^a   Kough, John ^b   Takeda, Shin ^c   Gyulay, Zsofia ^a   Plotkin, Stanley A ^d   Rando, Robert F ^e,f  

^a WISTAR INSTITUTE   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Pasteur Merieux Connaught   (France)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f Antigenics Inc   (United States)

Author keywords

Ad HCMV recombinants; CTL epitope; HCMV; IE1 exon 4

Indexed keywords

CYTOMEGALOVIRUS VACCINE; IMMEDIATE EARLY PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0343396361     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00227-R     Document Type: Article

References (37)

1. Alford, C.A. and Britt, W.J. Cytomegaloviruses. In: Virology (Eds Fields, B.N. and Knipe, D.M.). Raven Press, New York, 1990, pp. 1981-2010
2. Weller, T.H. The cytomegalovirus: ubiquitous agents with protein clinical manifestations. N. Engl. J. Med. 1971, 285, 203-214
3. Ho, M. Human cytomegalovirus infections in immuno-suppressed patients. In: Cytomegalovirus, Biology, and Infection: Current Topics in Infectious Disease (Eds Greenough, III, W.B. and T. Merigan, T.). Plenum Press, New York, 1982, pp. 171-204
4. Melnick, J.L., Adams, E. and DeBakey, M.E. Human cytomegalovirus and atherogenesis. In: Frontiers of Virology (Eds Becker, Y., Darai, G. and Huang, E.S.). Springer, New York, 1993, pp. 80-91
5. Speir, E., Modali, R., Huang, E.-Sh. et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994, 265, 391-394
6. Riddell, S.R., Rabin, M., Geballe, A.P., Britt, W.J. and Greenberg, P.D. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J. Immunol. 1991, 146, 2795-2804
7. + cytotoxic T lymphocyte responses to human cytomegalovirus in immunodeficient humans by the adoptive transfer of T cell clones. In: Multidisciplinary Approach to Understanding Cytomegalovirus Disease (Eds Michelson, S. and Plotkin, S.). Elsevier Science Publishers B.V., Amsterdam, 1993, pp. 155-164
8. Borysiewicz, L., Hickling, J., Graham, S., Sinclair, J., Cranage, M., Smith, G. and Sissons, J. Human cytomegalovirus specific cytotoxic T cells-relative frequency of stage specific CTL recognizing the 72 kDa immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J. Exp. Med. 1988, 168, 919-931
9. Britt, W.J., Vugler, L., Butfiloski, E.J. and Stephens, E.B. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J. Virol. 1990, 64, 1079-1085
10. Gönczöl, E., deTaisne, C., Hirka, G., Berencsi, K., Lin, W., Paoletti, E. and Plotkin, S.A. High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity. Vaccine 1991, 9, 631-637
11. Liu, Y.-N.C., Klaus, A., Kari, B., Stinski, M.F., Eckhardt, J. and Gehrz, R.C. Molecular analysis of the immune response to human cytomegalovirus glycoprotein B. I. Mapping of HLA-restricted helper T cell epitopes on gp93. J. Virol. 1991, 65, 1644-1648
12. Liu, Y.N., Curtsinger, J., Donahue, P.R. et al. The N-terminal 513 amino acids of the envelope glycoprotein gB of human cytomegalovirus stimulate both B- and T-cell immune responses in humans. J. Gen. Virol. 1993, 74, 2207-2214
13. Curtsinger, J.M., Liu, Y.-N.C., Radeke, R. et al. Molecular analysis of the immune response to human cytomegalovirus glycoprotein B (gB). II. Low gB-specific T and B cell responses are associated with expression of certain HLA-DR alleles. J. Gen. Virol. 1994, 75, 301-307
14. Marshall, G.S., Rabalais, G.P., Stout, G.G. and Waldeyer, S.L. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J. Infect. Dis. 1992, 165, 381-384
15. Pereira, L., Lennette, E., Paz, P. and Navarro, D. Humoral immunity to glycoprotein B in primary and recurrent human cytomegalovirus infections. In: Multidisciplinary Approach to Understanding Cytomegalovirus Disease (Eds Michelson, S. and Plotkin, S.). Elsevier Science Publishers B.V., Amsterdam, 1993, pp. 145-148
16. Rasmussen, L., Nelson, M., Neff, M. and Merigan, T.C. Jr. Characterization of two different human cytomegalovirus glycoproteins which are targets for virus neutralizing antibody. Virology 1988, 163, 308-318
17. Beninga, J., Kropff, B. and Mach, M. Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response. J. Gen. Virol. 1995, 76, 153-160
18. Banks, T., Huo, B., Kousoulas, K., Spaete, R., Pachi, C. and Pereira, L. A major neutralizing domain maps within the carboxyl-terminal half of the cleaved cytomegalovirus B glycoprotein. J. Gen. Virol. 1989, 70, 979-985
19. Qadri, I., Navarro, D., Paz, P. and Pereira, L. Assembly of conformation-dependent neutralizing domains on glycoprotein B of human cytomegalovirus. J. Gen. Virol. 1992, 73, 2913-2921
20. Gönczöl, E., Ianacone, J., Ho, W., Starr, S., Meignier, B. and Plotkin, S.A. Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 1990, 8, 130-136
21. Berencsi, K., Gönczöl, E., Valyi-Nagy, T. et al. Recombinant human cytomegalovirus (HCMV)-gB glycoprotein induces gB-specific cell-mediated immunity in mice. In: Proceedings of the Third International Cytomegalovirus Workshop, Bologna (Ed. Landini, M.P.). Elsevier Science Publishers, Netherlands, 1991, pp. 191-194
22. Berencsi, K., Rando, R.F., deTaisne, C., Paoletti, E., Plotkin, S.A. and Gönczöl, E. Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB. J. Gen. Virol. 1993, 74, 2507-2512
23. Gönczöl, E., Berencsi, K., Pincus, S. et al. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 1995, 13, 1080-1085
24. Utz, U., Koenig, S., Coligan, J.E. and Biddison, W.E. Presentation of three different viral peptides, HTLV-1, TAX, HCMV gB, and influenza virus M1, is determined by common structural features of the HLA-A2.1 molecule. J. Immunol. 1992, 149, 214-221
25. Alp, N.J., Allport, T.D., Van, Z.J., Rodgers, B., Sissons, J.G. and Borysiewicz, L.K. Fine specificity of cellular immune response in humans to human cytomegalovirus immediate - early 1 protein. J. Virol. 1991, 65, 4812-4820
26. Marshall, G.S., Ricciardi, R.P., Rando, R. et al. An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies. J. Infect. Dis. 1990, 162, 1177-1181
27. Berencsi, K., Uri, A., Valyi-Nagy, T. et al. Early region 3-replacement adenovirus recombinants are less pathogenic in cotton rats and mice than early region 3-deleted viruses. Lab. invest. 1994, 71, 350-358
28. Pizzorno, M.C., O'Hare, P., Sha, L., LaTenina, R.L. and Hayward, G.S. Transactivation and autoregulation of gene expression by the immediate-early 2 gene products of human cytomegalovirus. J. Virol. 1988, 62, 1167-1179
29. Stenberg, R.M., Thomsen, D.R. and Stinski, M.I. Structural analysis of the major immediate-early gene of human cytomegalovirus. J. Virol. 1984, 49, 190-199
30. Spaete, R.R., Thayer, R.M., Probert, W.S. et al. Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology 1988, 167, 207-225
31. Kari, B., Liu, Y.N., Goertz, R., Lussenhop, N., Stinski, M.F. and Gehrz, R. Structure and composition of a family of human cytomegalovirus glycoprotein complexes designated gCl (gB). J. Gen. Virol. 1990, 71, 2673-2680
32. Gönczöl, E., Furlini, G., Ianacone, J. and Plotkin, S.A. A rapid microneutralization assay for cytomegalovirus. J. Virol. Meth. 1986, 14, 37-41
33. Hornbeck, P. Enzyme-linked immunoadsorbent assays. In: Current Protocols in Immunology (Eds Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Sherach, E.M. and Strober, W.). John Wiley and Sons, New York, 1991, pp. 2.1.2-2.1.22
34. Mocarski, E.S. Cytomegalovirus biology and replication. In: The Human Herpesviruses (Eds Roizman, B., Whitley, R.J. and Lopez, C.). Raven Press, New York, 1993, pp. 173-226
35. Quinnan, G.V. Jr., Kirmani, N., Rook, A.H. et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N. Engl. J. Med. 1982, 307, 7-13
36. Reusser, P., Riddell, S.R., Meyers, J.D. and Greenberg, P.D. T-lymphocyte response to cytomegalovirus after human allogenic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991, 78, 1373-1380
37. Gilbert, M.J., Riddell, S.R., Li, C.-R. and Greenberg, P.D. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J. Virol. 1993, 67, 3461-3469